Article Index - HemaSphere - Wiley Online Library

Actions

Tools

Follow journal

All HemaSphere Articles

Filters

1-20 of 347 results

Relevance

Export Citation(s)Download PDF(s)

LETTER
Open Access

oa

Clonal hematopoiesis of indeterminate potential (CHIP) and risk of non-Hodgkin lymphoma: A community-based cohort study
Mingcheng Liu, Luyao Zhou, Qiaoxue Liu, Xiaojing Wang, Hui Wei, Qianwei Liu,

First published: 27 July 2025
ARTICLE
Open Access

oa

Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer
Christian Brieghel, Thomas Lacoppidan, Esben Packness, Casper Møller Frederiksen, Mikkel Werling, Michael Asger Andersen, Christian Bjørn Poulsen, Emelie Curovic Rotbain, Carsten Utoft Niemann,

First published: 16 July 2025

Graphical Abstract
ARTICLE
Open Access

oa

Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study
Giovanni Manfredi Assanto, Eleonora Alma, Alessandro Cellini, Giovanni Marsili, Gianluca Maiorana, Cristina Santoro, Martina Salvatori, Natalia Cenfra, Vladimir Otasevic, Darko Antic, Gianna Maria D'Elia, Maria Paola Bianchi, Giorgia Annechini, Silvio Ligia, Alessandro Pulsoni, Agostino Tafuri, Andrea Visentin, Alfonso Piciocchi, Stefan Hohaus, Maurizio Martelli, Ilaria Del Giudice, Antonio Chistolini,

First published: 13 July 2025

Graphical Abstract
ARTICLE
Open Access

oa

Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study
Kyung Taek Hong, Jung Yoon Choi, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee Young Ju, Keon Hee Yoo, Eu Jeen Yang, Sung-Soo Yoon, Hyeon Jin Park, Hyoung Soo Choi, Hee Won Chueh, Deok-Hwan Yang, Joon Ho Moon, Jae Min Lee, Jung-Hee Lee, Jeong-A Kim, Jong-Ho Won, Hyoung Jin Kang,

First published: 17 June 2025
LETTER
Open Access

oa

Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?
Mattias Carlsten, Elisa Linnea Lindfors Rossi, Martin Jädersten, Bianca Tesi, Sulaf Abd Own, Brigitta Sander, Stefan Deneberg, Anne Ivinskiy, Kristina Sonnevi, Hanna Sjölund, Gunilla Enblad, Björn Wahlin, Stephan Mielke,

First published: 05 June 2025
ARTICLE
Open Access

oa

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials
Celia González-Gil, Thaysa Lopes, Mireia Morgades, Francisco Fuster-Tormo, Pau Montesinos, Carlos Rodríguez Medina, Lourdes Hermosín, Teresa González-Martínez, María-Paz Queipo, José González-Campos, Pilar Martínez-Sánchez, Marina Díaz-Beya, Rosa Coll, Clara Maluquer, Lurdes Zamora, Teresa Artola, Ferran Vall-Llovera, Mar Tormo, Anna Torrent, Carolina Martínez-Laperche, Cristina Gil-Cortés, Pere Barba, Marta Cervera, Jordi Ribera, Manuel Fernández-Delgado, Rosa Ayala, Antonia Cladera, María Carmen Mateos, María Jesús Vidal, Jesús Feliu, Ana Torres, Gemma Azaceta, María José Calasanz, Anna Bigas, Manel Esteller, Alberto Orfao, Josep Maria Ribera, Eulalia Genescà,

First published: 26 May 2025

Graphical Abstract
LETTER
Open Access

oa

Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia
Rebeqa Gunnarsson, Minjun Yang, Andrea Biloglav, Kristina B. Lundin-Ström, Henrik Lilljebjörn, Anders Castor, Thoas Fioretos, Linda Olsson-Arvidsson, Kajsa Paulsson, Bertil Johansson,

First published: 19 May 2025

Collections: Pediatric Hematology
ARTICLE
Open Access

oa

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma
Matthew Mei, Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen, Ni-Chun Tsai, Saro Armenian, James Godfrey, Joo Y. Song, John H. Baird, Swetha Thiruvengadam, Yazeed Samara, Jessica Flores, Lacolle Peters, Steven Rosen, Larry Kwak, Stephen J. Forman, Alex F. Herrera,

First published: 30 April 2025

Graphical Abstract

$Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma$
ARTICLE
Open Access

oa

Comparing functional and genomic-based precision medicine in blood cancer patients
Lukas Kazianka, Alexander Pichler, Christiane Agreiter, Johannes Rohrbeck, Christoph Kornauth, Edit Porpaczy, Christian Sillaber, Wolfgang R. Sperr, Karoline V. Gleixner, Alexander Hauswirth, Ulrich Jäger, Peter Valent, Constanze Jonak, Stefanie Porkert, Ruth Exner, Wolfgang Willenbacher, Dominik Wolf, Peter Neumeister, Katharina Prochazka, Alexander Deutsch, Richard Greil, Clemens Schmitt, Robin Ristl, Marius Mayerhoefer, Ingrid Simonitsch-Klupp, Tea Pemovska, Philipp B. Staber,

First published: 24 April 2025

Graphical Abstract
REVIEW ARTICLE
Open Access

oa

Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B-cell lymphoma
Flore Sneyers, Ana-Lucía Rocha-Iraizos, Vibeke K. J. Vergote, Daan Dierickx,

First published: 15 April 2025

Collections: Reviews
ARTICLE
Open Access

oa

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study
Martijn W. C. Verbeek, Michaela Reiterová, Anna Laqua, Beatriz Soriano Rodríguez, Lukasz Sedek, Chiara Buracchi, Malicorne Buysse, Elen Oliveira, Robby Engelmann, Joana Desterro, Anja X. De Jong, Sebastian Boettcher, Romana Jugooa, Susana Barrena, Saskia Kohlscheen, Stefan Nierkens, Joana G. Rodriques, Mattias Hofmans, Giuseppe Gaipa, Elaine Sobral de Costa, Ester Mejstrikova, Tomasz Szczepanski, Monika Brüggemann, Jacques J. M. van Dongen, Alberto Orfao, Vincent H. J. van der Velden,

First published: 13 April 2025

Graphical Abstract
PERSPECTIVE
Open Access

oa

Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
Jean-Michel Cayuela, Pierre Sujobert, Pascale Flandrin-Gresta, Anne-Sophie Alary, Carole Maute, Damien Luque-Paz, Cédric Pastoret, Stéphanie Dulucq, Audrey Gauthier, Meryl Darlington, Isabelle Durand-Zaleski, Olivier Kosmider, Elizabeth Macintyre,

First published: 08 April 2025
ARTICLE
Open Access

oa

NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk
Krystof Seferna, Michael Svaton, Andrea Rennerova, Aneta Skotnicova, Leona Reznickova, Tatana Valova, Petr Sedlacek, Petr Riha, Renata Formankova, Petra Keslova, Lucie Sramkova, Jan Stary, Jan Zuna, Alexandra Kolenova, Cyril Salek, Jan Trka, Eva Fronkova,

First published: 08 April 2025
ARTICLE
Open Access

oa

H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia
Vera H. Jepsen, Andrea Hanel, Daniel Picard, Rigveda Bhave, Rebecca Hasselmann, Juha Mehtonen, Julian Schliehe-Diecks, Carla-Johanna Kath, Vithusan Suppiyar, Yash Prasad, Katerina Schaal, Jia-Wey Tu, Nadine Rüchel, Ersen Kameri, Nan Qin, Herui Wang, Zhengping Zhuang, Rabea Wagener, Lena Blümel, Tobias Lautwein, Daniel Hein, David Koppstein, Gesine Kögler, Marc Remke, Sanil Bhatia, Merja Heinäniemi, Arndt Borkhardt, Ute Fischer,

First published: 02 April 2025

Graphical Abstract
PERSPECTIVE
Open Access

oa

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
John G. Gribben, Leticia Quintanilla-Martinez, Simon Crompton, Jann Arends, Christophe Bardin, Heiko Becker, Frederic Castinetti, Dégi L. Csaba, Melvin D'Anastasi, Thomas Frese, Jan Geissler, Reda Matuzeviciene, Marius E. Mayerhoefer, Rui Medeiros, Kate Morgan, Šarūnas Narbutas, Samantha Nier, Umberto Ricardi, Eugenia Trigoso Arjona, Mehmet Ungan, Lorna Warwick, Emanuele Zucca,

First published: 31 March 2025
ARTICLE
Open Access

oa

TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort
Yangyang Gao, Jun Li, Ning Wang, Wenbin An, Zixi Yin, Junxia Wang, Xia Chen, Yumei Chen, Ye Guo, Wenyu Yang, Li Zhang, Yao Zou, Xiaojuan Chen, Xiaofan Zhu,

First published: 31 March 2025

Collections: Pediatric Hematology

Graphical Abstract
LETTER
Open Access

oa

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study
Claudia Bellofiore, Marco Basset, Giuseppe Damiano Sanna, Andrea Foli, Roberta Mussinelli, Martina Nanci, Alessandro Fogliani, Martina Ciardo, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini, Paolo Milani,

First published: 24 March 2025
LETTER
Open Access

oa

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients
Rita Tavarozzi, Simone Ferrero, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Michael Mian, Manuela Zanni, Federica Cavallo, Alice Di Rocco, Vittorio Stefoni, Chiara Pagani, Alessandro Re, Barbara Botto, Monica Balzarotti, Vittorio R. Zilioli, Maria Gomes da Silva, Luca Arcaini, Anna L. Molinari, Filippo Ballerini, Andrés J. M. Ferreri, Benedetta Puccini, Carlo Visco, Piero M. Stefani, Mario Luppi, Ivana Casaroli, Caterina Stelitano, Giovannino Ciccone, Umberto Vitolo, Maurizio Martelli, Sergio Cortelazzo, Marco Ladetto,

First published: 22 March 2025
LETTER
Open Access

oa

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial
Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Johan Linderoth, Peter M. H. Kamper, Sirpa M. Leppä, Julia Meissner, Valdete Schaub, Kjersti Lia, Michael Fuchs, Peter Borchmann, Boris Böll,

First published: 21 March 2025
ARTICLE
Open Access

oa

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
Elin Forsgren, Rasmus R. K. Jørgensen, Hans Bentzen, Jon Riise, Jacob Haaber, Annika Pasanen, Hanne Kuitunen, Karin F. Wader, Tarec C. El-Galaly, Martin Hutchings, Ingrid Glimelius, Mats Jerkeman,

First published: 18 March 2025

Graphical Abstract

Tools

Follow journal

HemaSphere

Applied Filters

Filters

All HemaSphere Articles

oa

Clonal hematopoiesis of indeterminate potential (CHIP) and risk of non-Hodgkin lymphoma: A community-based cohort study

oa

Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer

Graphical Abstract

oa

Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study

Graphical Abstract

oa

Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study

oa

Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?

oa

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

Graphical Abstract

oa

Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia

oa

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma

Graphical Abstract

oa

Comparing functional and genomic-based precision medicine in blood cancer patients

Graphical Abstract

oa

Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B-cell lymphoma

oa

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study

Graphical Abstract

oa

Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)

oa

NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

oa

H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

Graphical Abstract

oa

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies

oa

TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort

Graphical Abstract

oa

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study

oa

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

oa

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial

oa

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Graphical Abstract

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Tools

Follow journal

HemaSphere

Applied Filters

Filters

Filter by Keyword

Subject Categories

Publication Date

ACCESS STATUS

Author

Article Category

All HemaSphere Articles

Download PDFs

oa Clonal hematopoiesis of indeterminate potential (CHIP) and risk of non-Hodgkin lymphoma: A community-based cohort study

oa Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer

Graphical Abstract

oa Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study

Graphical Abstract

oa Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study

oa Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?

oa Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

Graphical Abstract

oa Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia

oa Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma

Graphical Abstract

oa Comparing functional and genomic-based precision medicine in blood cancer patients

Graphical Abstract

oa Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B-cell lymphoma

oa Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study

Graphical Abstract

oa Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)

oa NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

oa H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

Graphical Abstract

oa European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies

oa TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort

Graphical Abstract

oa Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study

oa Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

oa Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial

oa Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Graphical Abstract

oa

Clonal hematopoiesis of indeterminate potential (CHIP) and risk of non-Hodgkin lymphoma: A community-based cohort study

oa

Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer

oa

Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study

oa

Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study

oa

Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?

oa

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

oa

Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia

oa

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma

oa

Comparing functional and genomic-based precision medicine in blood cancer patients

oa

Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B-cell lymphoma

oa

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study

oa

Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)

oa

NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

oa

H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

oa

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies

oa

TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort

oa

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study

oa

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

oa

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial

oa

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial